In addition, PBEF serum expression levels were measured by ELISA and correlated with genotypes.

Results In two separate populations and in a meta-analysis, the combined *PBEF* -1543CC -1001TT genotype, hence carrying no minor alleles, was found associated with SSc susceptibility ($p=0.009$ OR 1.20 (95% CI 1.05 to 1.37)). In addition, these subjects showed an increased decline in forced vital capacity over 15 years follow-up ($p=0.02$) (HR 1.64, 95% CI 1.02 to 2.64) and a higher PBEF serum concentration ($p<0.01$), compared to carriers of minor alleles. On the other hand, patients with genotype *PBEF* -1001TT were at lower risk for PAH development within 15 years of disease onset compared to the carriers with genotypes *PBEF* -1001GG and *PBEF* -1001TG ($p<0.001$) (HR 3.29, 95% CI 1.52 to 7.12).

Conclusions This data identify PBEF as a novel candidate gene that influences SSc susceptibility, pulmonary function and the development of PAH.

A45 VARIANTS OF PBEF PREDISPOSE TO SYSTEMIC SCLEROSIS AND PULMONARY ARTERIAL HYPERTENSION DEVELOPMENT

J C A Broen,¹ P Gourh,² M C Vonk,¹ L Beretta,³ F Niederer,⁴ B Rueda,⁵ L Geurts-van Bon,¹ C Brouwer,¹ R Hesselstrand,⁶ A Herrick,⁷ J Worthington,⁷ N Hunzelman,⁸ Denton C Fonseca,⁹ G Riemekasten,¹⁰ H Kiener,¹¹ R Scorza,³ C P Simeon,¹² V Fonollosa,¹² (for the Spanish Systemic Sclerosis group), P Carreira,¹³ N Ortego-Centeno,¹⁴ M A Gonzalez-Gay,¹⁵ P Airo,¹⁶ M J H Coenen,¹⁷ M Mayes,² D Kyburz,⁴ F C Arnett,² J Martin,⁵ T R D J Radstake¹ ¹Department of Rheumatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands; ²Department of Internal Medicine, Division of Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston (UTHSC-H), Houston, Texas, USA; ³Referral Center for Systemic Autoimmune Diseases, University of Milan, Milan, Italy; ⁴Division of Rheumatology, University Hospital Zurich, Zürich, Switzerland; ⁵Instituto de Parasitología y Biomedicina, CSIC, Granada, Spain; ⁶Department of Rheumatology, Lund University Hospital, Lund, Sweden; ⁷Rheumatic Diseases Centre, University of Manchester, Salford Royal NHS Foundation Trust, Manchester, UK; ⁸Department of Dermatology, University of Cologne, Cologne, Germany; ⁹Centre for Rheumatology, Royal Free and University College Medical School, London, UK; ¹⁰Department of Rheumatology and Clinical Immunology, Charité University Hospital and German Rheumatism Research Centre, a Leibniz institute, Berlin, Germany; ¹¹Department of Internal Medicine, Division of Rheumatology, University of Vienna, Vienna, Austria; ¹²Servicio de Medicina Interna, Hospital Vall d'Hebron, Barcelona, Spain; ¹³Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain; ¹⁴Servicio de Medicina Interna, Hospital Clínico Universitario, Granada, Spain; ¹⁵Servicio de Reumatología, Hospital Marques de Valdecillas, Santander, Spain; ¹⁶Servizio di Reumatologia ed Immunologia Clinica, Spedali Civili, Brescia, Italy; ¹⁷Department of Human Genetics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

JCAB, PG, MCV, FCA, JM and TRDJR contributed equally to this work

10.1136/ard.2010.148965.15

Aim Pre-B cell colony-enhancing factor (PBEF) is intricately involved in inflammation and fibrosis, functional polymorphisms of PBEF have been previously shown to influence PBEF expression and pulmonary damage. Systemic sclerosis (SSc) is a disease in which inflammation, fibrosis and pulmonary deterioration are prominent hallmarks. Therefore the authors here investigate the role of the *PBEF* -1001T>G and *PBEF* -1543C>T polymorphisms in the genetic predisposition to SSc susceptibility and pulmonary involvement.

Patients and methods The authors genotyped DNA from 2737 SSc patients and 1913 matched healthy controls, both from eight different ethnic populations. Genotyping was performed using custom Taqman 5' allelic discrimination assays.